Treatment of emotional and cognitive disorders in patients with chronic cerebral ischemia

Kamchatnov P.R.; Vorob'eva O.V.; Rachin A.P.

doi:https://doi.org/

Kamchatnov P.R.

Kafedra nevrologii i neĭrokhirurgii Rossiĭskogo gosudarstvennogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

SPIN RSCI: 9240-6754
Scopus AuthorID: 6602401209
ORCID: 0000-0001-6747-3476

Vorob'eva O.V.

Kafedra nervnykh bolezneĭ fakul'teta poslevuzovskogo professional'nogo obrazovaniia vracheĭ

Rachin A.P.

Kafedra nevrologii i psikhiatrii fakulteta povysheniia kvalifikatsii Smolenskoĭ gosudarstvennoĭ meditsinskoĭ akademii

ORCID: 0000-0003-4266-0050

Treatment of emotional and cognitive disorders in patients with chronic cerebral ischemia

Authors:

Kamchatnov P.R., Vorob'eva O.V., Rachin A.P.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(4): 52‑56

Read: 1772 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kamchatnov PR, Vorob'eva OV, Rachin AP. Treatment of emotional and cognitive disorders in patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(4):52‑56. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Cognitive impairment in asthenic disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):27-32

Experience of using reamberin for correction of cognitive status in patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):84-88

Quantitative and qualitative assessment of the complete blood count in patients with obstructive sleep apnea and chronic ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):95-102

Targets of rational neuroprotection in the therapy of chronic cerebral ischemia and the possibilities of achieving them. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):96-101

Hysterical disorders in patients with hematological diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):71-78

Attention deficit hyperactivity disorder: pharmacotherapy in special situations. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):59-65

Results of the observational program CITOTREK (use of the drug CITOflavin in Tablets) in patients with tension headaches against the backgRound of asthenic syndromE taKing into account comorbidity. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):104-112

Cogitum in the treatment of mental disorders in childhood. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):88-95

Mitochondrial cytoprotectors in complex therapy of chronic heart failure in patients with metabolic syndrome or type 2 diabetes mellitus: subanalysis of the INDIKOR study. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(5):566-576

Depressive disorders in women during the menopausal transition and menopause. Russian Bulletin of Obstetrician-Gynecologist. 2025;(5):41-46

Abstract:

Objective: To study clinical efficacy of the drug divasa in patients with chronic cerebral ischemia. Material and methods: One hundred and forty-two patients, mean age 58,6±8,8 years, were treated during 11,9±0,2 weeks. Neurological examination and evaluation of a patient's status with psychometric scales were performed. Results: The drug reduced anxiety, depressive and asthenic disorders beginning from the 4th week of treatment. The positive effect of treatment on cognitive functions appeared later. Conclusion: Divasa proved to be an effective drug in the complex treatment of patients with chronic disturbances of cerebral blood circulation.

Keywords:

chronic cerebral ischemia

anxiety disorders

depressive disorders

asthenia

divasa